文献速递胸部CTPETMR

肺癌化疗及靶向治疗后的胸部影像学表现

Post-chemotherapy and targeted therapy imaging of the chest in lung cancer.
PubMed 文献 · Clin Radiol · 2021-09-17

本文综述了晚期非小细胞肺癌(NSCLC)全身治疗(化疗及靶向治疗)的现状,重点阐述了不同基因突变(如EGFR、ALK)的影像学特征、疗效评估中的陷阱以及并发症的影像学表现,旨在帮助放射科医生在个性化治疗时代准确解读胸部影像。

要点

  • 晚期NSCLC治疗已从统一化疗转向基于生物标志物(如EGFR突变、ALK重排、PD-L1表达)的个性化策略。
  • 认识EGFR突变和ALK重排肿瘤的影像学特征有助于提示基因分型。
  • 疗效评估需注意靶向治疗后的非典型反应模式及并发症,避免误判。

关键影像表现/征象

  • EGFR突变和ALK重排导致肿瘤细胞失控生长和增殖,可被酪氨酸激酶抑制剂(TKIs)靶向治疗。
  • 原文提及综述了突变相关的影像学特征,但未具体描述征象。

临床应用与阅片要点

  • 在阅片和报告中,应结合患者的基因突变状态(如EGFR、ALK)和靶向治疗史,注意识别治疗相关的影像学改变。
  • 评估疗效时需警惕靶向治疗后的非典型反应模式,避免将治疗相关改变误判为进展。
  • 关注靶向治疗和化疗的并发症影像表现,及时识别并报告。

局限性

  • 本文为综述,未提供原始研究数据或系统评价方法。
  • 原文未具体描述影像学征象、诊断标准或数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Non-small-cell lung cancer (NSCLC) is frequently diagnosed when it is not amenable to local therapies; therefore, systemic agents are the mainstay of therapy for many patients. In recent years, treatment of advanced NSCLC has evolved from a general approach primarily involving chemotherapy to a more personalised strategy in which biomarkers such as the presence of genomic tumour aberrations and the expression of immune proteins such as programmed death-ligand 1 (PD-L1), in combination with other elements of clinical information such as histology and clinical stage, guide management. For instance, pathways resulting in uncontrolled growth and proliferation of tumour cells due to epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements may be targeted by tyrosine kinase inhibitors (TKIs). In this article, we review the current state of medical oncology, imaging characteristics of mutations, pitfalls in response assessments and the imaging of complications.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Carter BW, Altan M, Shroff GS, et al. Post-chemotherapy and targeted therapy imaging of the chest in lung cancer. Clin Radiol. 2021. PMID: 34538577. doi:10.1016/j.crad.2021.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。